New drug developed by Shenzhen micro-core bio-developed is granted by U.S. invention patent

recently, Shenzhen Microcore Biotech Co., Ltdindependent research and development is in the clinical development stage of the anti-
tumorlead compound Sidabenamine (CS
55
) by the United States invention patent granted, the product has been patented in China in 2006Sidabenamine is an oral bio-available histone deacetylase (HDAC) inhibitor derived from the paraphenylamine categoryHistone deacetylase inhibitors are a class of anti-
tumor
new drugs that can cause selective regulation of gene expression intumorcellsSidabenamine has exhibited preclinical efficacy and pharmacokinetic properties, which means that the clinical properties of cydabenamines are more prominent than other histone deacetylase inhibitors currently being developed or soldIt is understood that Shenzhen Microcore Biotech Co., Ltdis a leading life science enterprise specializing in research and development of patented small molecular therapy (especially in the field of receptor signaling), with integrated silicon research and design, high-content screening, pathway expression spectrum, PK/PD screening and other core capabilities, using its advanced computer and medical chemistry in Shenzhen, amplification synthesis, natural product chemistry, formulation, analytical method development and verification, biology, high-throughput screening, microarray and information resources have been improved and acceleratedAt present, Sidabenamine has been approved to carry out Phase I clinical trials in China, its clinical trials outside China by HUYA Biological Sciences International Co., Ltdexclusive agent HuYA will jointly develop sidabenamine with micro-core biotechnology in the upcoming Phase I clinical trial in China HuYA then plans to submit applications for new drugs and begin clinical trials of silamine in the United States and Europe (reproduced from the China High-tech Industry Guide)